Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PROGNOSTIC-FACTORS. Found 14 abstracts

Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu YH, Schwartz JD, Thompson JA. A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. Cancer. 2014 Jun;120(11):1647-55.   PMCID: No NIH funding
Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T Cells and Tumor Proliferation. Cancer. 2009 Jul;115(13):2891-902.   PMCID: PMC2754811
DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, ACOSOG Intergrp Adjuvant GIST Stud. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009 Mar;373(9669):1097-104.   PMCID: PMC2915459
Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665. Journal of surgical oncology. 2009 Jan;99(1):42-7.   PMCID: PMC2606912
Ivanov SV, Miller J, Lucito R, Tang CL, Ivanova AV, Pei JM, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. Genomic events associated with progression of pleural malignant mesothelioma. International journal of cancer. 2009 Feb;124(3):589-99.   PMCID: PMC2933144
Tian CQ, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK, Gynecologic Oncology Grp Study; Gynecologic Oncology Grp S. CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study. Cancer. 2009 Apr;115(7):1395-403.   PMCID: PMC 2743569
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology. 2008 Feb;26(4):626-32.
Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. Journal of Clinical Oncology. 2008 Mar;26(9):1465-71.
Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):353-60.
Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 2008 Apr;61(4):689-94.
Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar A, Motwani SB, Tereffe W, Yu TK, Sher D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small W. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):477-84.
Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K, Bruner DW. Emotional well-being does not predict survival in head and neck cancer patients - A radiation therapy oncology group study. Cancer. 2007 Dec;110(11):2568-75.
Langer C, Li SG, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599. Journal of Clinical Oncology. 2007 Feb;25(4):418-23.
Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW, Peacock S, Apicella C, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL. Treatment of patients with metastatic renal cell cancer - A RAND appropriateness panel. A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services. Cancer. 2006 Nov;95(10):1448-53.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PROGNOSTIC-FACTORS

PROGNOSTIC-FACTORS SURVIVAL CARCINOMA CHEMOTHERAPY PHASE-III MUTATIONS CANCER SURGERY FOLLOW-UP renal cell carcinoma CELL LUNG-CANCER breast cancer PROGRESSION INHIBITOR BREAST-CANCER SALVAGE MASTECTOMY SOLID TUMORS local recurrence III TRIAL GENE-EXPRESSION EPITHELIAL OVARIAN-CANCER COMBINATION RESECTION EUROPEAN-ORGANIZATION HEALTH OVARIAN-CANCER BRCA1 and BRCA2 CONJOINT-ANALYSIS health-related quality of life TYROSINE KINASE angiogenesis MALIGNANT-MELANOMA clear cell cancer CA-125-mucinous cell cancer-ovarian cancer metastatic GIST MICROARRAY ANALYSIS phase 2 SARCOMA-GROUP REGIMENS T cells ovarian cancer-surgical cytoreduction-tumor proliferation EFFICACY LEIOMYOSARCOMAS FUNCTIONAL ASSESSMENT RESISTANCE CONSERVING PRETREATMENT CA-125 INFILTRATING LYMPHOCYTES LEUKEMIA GROUP-B QUALITY-OF-LIFE prognostic survival locoregional control GTI-2040 renal cancer-ribonucleotide reductase-capecitabine-fluoropyrimidine RADIATION-THERAPY ramucirumab neoplasm metastasis RESIDUAL DISEASE GIST mesothelioma R2 5-FLUOROURACIL DISEASE genetic counselling HYPERTHERMIA CGH VINDESINE EXPRESSION HEALTH-CARE RECURRENCE depression cancer PRIMARY CYTOREDUCTIVE SURGERY TRIAL IMATINIB immunotherapy PSYCHOLOGICAL RESPONSE RANDOMIZED PHASE-II PROSTATE-CANCER EPIDEMIC RIBONUCLEOTIDE REDUCTASE oncogenes ELDERLY-PATIENTS psychosocial INFORMATION N-CADHERIN HIGH-DOSE THERAPY monoclonal GROUP EXPERIENCE HUMAN-CHROMOSOME 3P213 radiotherapy nephrectomy tumor suppressors CISPLATIN client preferences Ashkenazi RADIOTHERAPY STAGE-III SURGICAL CYTOREDUCTION INFUSION TOXICITY CRITERIA MYELOGENOUS LEUKEMIA GEMCITABINE EORTC QLQ-C30 antibody SELECTION Oncology BRCA2 MUTATIONS INTRAVENOUS CISPLATIN PLUS COMMON BRCA1 practice guidelines KIT PATTERNS inhibitors DOSE IMATINIB SURGICAL-MANAGEMENT FAMILIAL BREAST metastatic ASHKENAZI JEWS VINORELBINE VALIDITY TUMORS neoadjuvant imatinib C-KIT repeat irradiation GROWTH HOMOZYGOUS DELETION REGION head and neck cancer ANTISENSE OLIGONUCLEOTIDE toxicity BONE-MARROW AUTOTRANSPLANTS OUTCOMES METASTATIC BREAST-CANCER RANDOMIZED-TRIAL ONCOSTATIN-M SUNITINIB INTERLEUKIN-2 ROMA discrete choice experiment copy number alterations TUMOR PLUS INTERFERON-ALPHA INTRAPERITONEAL CISPLATIN PHASE-III TRIAL BLOOD-CELL CONSERVATION THERAPY well-being emotional PSYCHOSOCIAL FACTORS GYNECOLOGIC-ONCOLOGY-GROUP SORAFENIB DOSE CHEMOTHERAPY
Last updated on Friday, December 06, 2019